Raba konoplje v medicinske namene
integrativni pregled literature
DOI:
https://doi.org/10.14528/snr.2021.55.4.3063Ključne besede:
kanabis, medicinska raba, zdravljenjePovzetek
Uvod: Slovenija je leta 2017 spremenila uredbo o razvrstitvi prepovedanih drog in omogočila uporabo konoplje v medicinske namene. Konoplja ima več kot 140 kanabinoidnih spojin, med katerimi sta najbolj izpostavljeni kanabidiol in tetrahidrokanabinol, saj imata potencial za zdravljenje bolezni. Namen pregleda je raziskati rabo konoplje v medicinske namene.
Metode: Izveden je bil integrativni pregled literature v digitalni zbirki podatkov PubMed, spletnem iskalniku Google učenjak in vzajemnemu bibliografskemu sistemu COBISS s pomočjo besednih zvez: »cannabis AND medical use«, »marihuana AND medical use« in »raba konoplje v medicinske namene«. Omejitve iskanja so bile: obdobje objave literature (2008–2019), prost dostop do recenziranih strokovnih in znanstvenih člankov ter literatura v angleškem ali slovenskem jeziku. Za pregled literature je bila uporabljena tematska analiza prebranega gradiva.
Rezultati: Za pregled literature je bilo za končno analizo primernih 29 člankov. Identificiranih je bilo 52 kod, združenih v štiri teme: (1) zdravljenje s konopljo, (2) lastnosti konoplje, (3) delovanje kanabidiola, (4) delovanje tetrahidrokanabinola.
Diskusija in zaključek: Konoplja se že tisočletja uporablja v medicinske namene. Danes jo v svetu uporabljajo predvsem za zdravljenje naslednjih bolezni: astme, diabetesa, epilepsije, raka, Parkinsonove bolezni, Alzheimerjeve demence, multiple skleroze. V Sloveniji je konoplja odstranjena s seznama najbolj nevarnih drog, a do njene rabe v medicinske namene je zahteven proces.
Prenosi
Metrike
Literatura
Abramovici, H. (2013). Information for health care proffessionals, cannabis (marihuana, marijuana) and the cannabinoids. Ottawa: Health Canada.
Aveyard, H. (2018). Doing a literature review in health and social care: A practical guide. London: McGraw-Hill Education.
Atakan, Z. (2012). Cannabis, a complex plant: Different compounds and different effects on individuals. Therapeutic Advances in Psychopharmacology, 2(6), 241–254. https://doi.org/10.1177/2045125312457586 PMid:23983983; PMCid:PMC3736954
Baron, E. P. (2015). Comprehensive review of medicinal marijuana, cannabinoids and therapeutic implications in medicine and headache: What a long strange trip it's been. Headache, 55(6), 885–916. https://doi.org/10.1111/head.12570 PMid:26015168
Bellnier, T., Brown, G. W., & Ortega, T. R. (2018). Preliminary evaluation of the efficacy, safety and costs associated with the treatment of chronic pain with medical cannabis. Mental Health Clinician, 8(3), 110–115. https://doi.org/10.9740/mhc.2018.05.110 PMid:29955555; PMCid:PMC6007634
Bonnet, U., & Preuss, U. W. (2017). The cannabis withdrawal syndrom: Current insights. Substance Abuse and Rehabilitation, 8, 9–37. https://doi.org/10.2147/SAR.S109576 PMid:28490916; PMCid:PMC5414724
Borgelt, L. M., Franson, K. L., Nussbaum, A. M., & Wang, G. S. (2013). The Pharmacologic and Clinical Effects of Medical Cannabis, 33(2), 195–209. https://doi.org/10.1002/phar.1187 PMid:23386598
Bučan, E., & Bregar, B. (2017). Uporaba novih psihoaktivnih snovi med študenti zdravstvenih in pedagoških poklicev. Obzornik zdravstvene nege, 51(1), 42–51. https://doi.org/10.14528/snr.2017.51.1.109
Budney, A. J., & Borodovsky, J. T. (2017). The potential impact of cannabis legalization on the development of cannabis use disorders. Preventive Medicine, 104, 31–36. https://doi.org/10.1016/j.ypmed.2017.06.034 PMid:28668544; PMCid:PMC5735001
Colbert, M. (2015). Indica, sativa, ruderalis: Did we get it all wrong. Retrieved May 6, 2021 from http://theleafonline.com/c/ science/2015/01/indica-sativa-ruderalis-get-wrong
Corey-Bloom, J., Wolfson, T., Gamst, A., Jin, S., Marcotte, T.D., Bentley, H., & Gouaux, B. (2012). Smoked cannabis for spasticity in multiple sclerosis: A randomized, placebocontrolled trial. Canadian Medical Association Journal, 184(10), 1143–1150. https://doi.org/10.1503/cmaj.110837 PMid:22586334; PMCid:PMC3394820
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2009). Translational investigation of the therapeutic potential of cannabidiol: Toward a new age. Frontiers in Immunology, 9, 33–89. https://doi.org/10.3389/fimmu.2018.02009 PMid:30298064; PMCid:PMC6161644
Čanji, P. (2018). Konoplja in kanabinoidi: pozitivna pridobitev ali prikrito zlo. Celje: Mestna občina Celje, Mladi za Celje. Retrieved October 31, 2019 from https://www.knjiznica-celje.si/raziskovalne/4201803590.pdf
Dariš, B., Tancer Verboten, M., Knez, Ž., & Ferk, P. (2018). Cannabinoids in cancer treatment: Therapeutic potential and legislation. Bosnian Journal of Basical Medical Sciences, 19(1), 14–23. https://doi.org/10.17305/bjbms.2018.3532 PMid:30172249; PMCid:PMC6387667
Dremelj, Z., Kastelic, A., & Kostnapfel Rihtar, T. (2012). Testiranje na prisotnost prepovedanih psihoaktivnih snovi. Ljubljana: Prohealth.
Ferjan, I., Kržan, M., Lipnik-Štangelj, M., Žiberna, L., Stanovnik, L., & Černe, K. (2015). Farmakologija kanabinoidov. Zdravstveni Vestnik, 84(6), 456–471. https://doi.org/10.6016/ZdravVestn.1360
Hancox, R. J., Shin, H. H., Gray, A. R., Poulton, R., & Sears, M. R. (2015). Effects of quitting cannabis on respiratory symptoms. European Respiratory Society, 46(1), 80−87. https://doi.org/10.1183/09031936.00228914 PMid:25837035; PMCid:PMC4780250
Herenda, D. (2017). Predlog sprememb in dopolnitev ZPrCP. Ljubljana: Nacionalni center za upravljanje prometa. Retrieved January 14, 2019 from http://odborzakonopljo.si/wp-content/ uploads/2017/12/Predlog-sprememb-in-doplonitev-ZPrCPNCUP.pdf
Hren, J., & Belščak, A. (2017). Drug policy workbook. In A. Drev, A. Hočevar Grom & A. Belščak (Eds.), Report on the Drug Situation 2017 of the Republic of Slovenia. Ljubljana: Nacionalni inštitut za javno zdravje.
King, L. A. (2004). An overview of cannabis potency in Europe. Luxembourg: Office for Official Publications of the European Communities.
Ko, G. D., Bober, S., Mindra, S., & Moreau, J. M. (2016). Medical cannabis: The Canadian perspective. Journal of Pain Research, 9, 735–744. https://doi.org/10.2147/JPR.S98182 PMid:27757048; PMCid:PMC5053383
Koprivnikar, H., Zupanič, T., Drev, A. & Jeriček Klanšček, H. (2019). Prevalence and characteristics of tobacco and cannabis co-use in 15 year-old students in Slovenia. Obzornik zdravstvene nege, 53(2), 104–111. https://doi.org/10.14528/snr.2019.53.1.259
Jacobson, C., & Porter, B. E. (2013). Survey of currennt cannabidiol use in pediatric treatment: Resistant epilepsy. Department of Neurology, Stanford University. Retrieved April 5, 2019 from: https://www.thcint.com/uploads/1/9/3/7/19371199/cannabidiol_ use_in_pediatric_epilepsy.pdf
Lochte, B., Beletsky, A., Samuel, N., & Grant, I. (2017). The use of cannabis for headache disorders. Cannabis and Cannabinoid Research, 2(1), 61–71. https://doi.org/10.1089/can.2016.0033 PMid:28861505; PMCid:PMC5436334
Marshall, K., Gowing, L., Ali, R., & Le Foll, B. (2014). Pharmacotherapies for cannabis dependence. Cochrane Database System reviews. https://doi.org/10.1002/14651858.CD008940.pub2 PMid:25515775; PMCid:PMC4297244
Martell, K., Fairdchild, A., LeGerrier, B., Sinha, R., Baker, S., Liu, H. … Kerba, M. (2018). Rates of cannabis use in patients with cancer. Current Oncology, 25(3), 219–225. https://doi.org/10.3747/co.25.3983 PMid:29962840; PMCid:PMC6023560
Meier, M., Caspi, A., Cerdá, M., Hancox, R. J., Harrington, H., Houts, R. … Moffitt, T.E. (2017). Associations between cannabis use and physical health problems in early midlife: A longitudinal comparison of persistent cananbis versus tobacco users. The journal of the American Medical Association Psychiatry, 73(7), 731–740. https://doi.org/10.1001/jamapsychiatry.2016.0637 PMid:27249330; PMCid:PMC4936934
Melnyk, B. Z., & Fineout-Overholt, E. (2015). Evidence-based practice in nursing & healthcare: A guide to best practice. Philadelphia: Wolters Kluwer Health.
Modesto-Lowe, V., Bojka, R., & Alvarado, C. (2018). Cannabis for peripheral neuropathy: The good, the bad and the unknown. Cleveland Clinic Journal of Medicine, 85(12), 943–949. https://doi.org/10.3949/ccjm.85a.17115 PMid:30526755
Mojaverrostami, S., Bojnordi, M. N., Ghasemi-Kasman, M., Ebrahimzadeh, M. A., & Hamidabadi, H. G. (2018). A review of herbal therapy in multiple sclerosis. Advanced Pharmaceutical Bulletin, 8(4), 575–590. https://doi.org/10.15171/apb.2018.066 PMid:30607330; PMCid:PMC6311642
Mouhamed, Y., Vishnyakov, A., Qorri, B., Sambi, M., Frank, S. S., Nowierski, C. … Bhatti, U. (2018). Therapeutic potential of medical marijuana: An educational primer for health care proffesionals. Drug Healthcare and Patient Safety, 10, 45–66. https://doi.org/10.2147/DHPS.S158592 PMid:29928146; PMCid:PMC6001746
Nacionalni inštitut za javno zdravje (NIJZ). (2015). Stanje na področju prepovedanih drog v Sloveniji. Ljubljana: Nacionalni inštitut za javno zdravje. Retreived January 20, 2019 from http://www.nijz.si/sites/www.nijz.si/files/publikacije-datoteke/nacionalno_porocilo_o_drogah_2015_0.pdf
Neubauer, D., Perkovič-Benedik, M., & Osredkar, D. (2019). Priporočila za uporabo kanabidiola in kanabinoidov (medicinske konoplje) v pediatriji: otroški nevrologiji. Ljubljana: Založba Univerze v Ljubljani, Medicinska fakulteta, Ustanova za otroško nevrologijo, Ljubljana. Retrieved August 15, 2019 from https:// www.institut-icanna.com/files/ULTIMO_Web.pdf
Noel, C. (2018). Evidence for the use of medical marijuana in psychiatric and neurologic disorders. Mental Health Clinician, 7(1), 29–38. https://doi.org/10.9740/mhc.2017.01.029 PMid:29955495; PMCid:PMC6007658
Nolimal, D. (2015). Ali strah pred medicinsko konopljo res hromi zdravnike. Revija ISIS, 14(7), 20–26.
Owens, B. (2015). Drug development: The treasure chest. Nature, 525(7570), 6–8. https://doi.org/10.1038/525S6a PMid:26398738
Pancer, J., & Dasgupta, K. (2019). Effects of cannabis use in youth and young adults with type 1 diabetes: The highs, the lows, the don't knows. Canadian Journal of Diabetes, 44(2), 121–127. https://doi.org/10.1016/j.jcjd.2019.05.001 PMid:31401053
Poli, P., Crestani, F., Salvadori, C., Valenti, I., & Sannino, C. (2017). Medical cannabis in patients with chronic pain: Effect on pain relief, pain dissability and psychological aspects: A prospective non randomized single arm clinical trial. Clinical Therapeutics, 169(3), 102–107.
Polit, D. F., & Beck, C. T. (2018). Essentials of nursing research: Appraising evidence for nursing practice (9th ed.) Philadelphia: Wolters Kluwer Health.
Predlog zakona o konoplji (2018). Retrieved January 20, 2019 from http://sksk.si/Predlog_zakona_o_konoplji.htm#_ Toc375388987
Robinson, R. (2015). Konopljin manifest: sto in en način, kako lahko konoplja reši svet. Visoko: Kiroja.
Scherma, M., Masia, P., Deidda, M., Fratta, W., Tanda, G., & Fadda, P. (2018). New perspectives on the use of cannabis in the treatment of psychiatric disorders. Medicines, 5(4), 107. https://doi.org/10.3390/medicines5040107 PMid:30279403; PMCid:PMC6313625
Self, T. H., Shah, S. P., March, K. L., & Sands, C. W. (2016). Asthma associated with the use of cocaine, heroin and marijuana: A review of the evidence. Journal of Asthma, 54(7), 714–722. https://doi.org/10.1080/02770903.2016.1259420 PMid:27858495
Stampanoni Bassi, M., Gilio, L., Dolcetti, E., Bruno, A., Buttari, F., Centonze, D., & Iezzi, E. (2018). Exploiting the multifaceted effects of cannabinoids on mood to boost their therapeutic use against anxiety and depression. Frontiers in Molecular Neuroscience, 11, 4–24. https://doi.org/10.3389/fnmol.2018.00424 PMid:30515077; PMCid:PMC6256035
Stith, S., Vigil, J. M., Brockelman, F., Keeling, K., & Hall, B.(2018). Patient-reported symptom relief following medical cannabis consumption. Frontiers in Pharmacology, 9, 9–16. https://doi.org/10.3389/fphar.2018.00916 PMid:30210337; PMCid:PMC6121171
Turna, J., Patterson, B., & Van Ameringen, M. (2017). Is cannabis treatment for anxiety, mood and related disorders ready for prime time. Journal of Depression and Anxiety, 34(11), 1006–1017. https://doi.org/10.1002/da.22664 PMid:28636769
Uredba o razvrstitvi prepovedanih drog. (2019). (Uradni list RS, št. 69/19 in 157/20) Retrieved April 22, 2021 from http://www.pisrs.si/Pis.web/ pregledPredpisa?id=URED7970
van Amsterdam, J., Vervloet, J., de Weert, G., Buwalda, V. J., Goudriaan, A. E., & van den Brink, W. (2018). Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia. Harm Reduction Journal, 15, Article 47. https://doi.org/10.1186/s12954-018-0253-7 PMid:30236118; PMCid:PMC6149068
Welch, V., Petticrew, M., Tugwell, P., Moher, D., O'Neill, J., Waters, E. … the PRISMA-Equity Bellagio group (2012). PRISMA-Equity 2012 Extension: Reporting guidelines for systematic reviews with a focus onhealth equity. Public Library of Science Medicine, 9(10), Article e1001333. https://doi.org/10.1371/journal.pmed.1001333 PMid:23222917; PMCid:PMC3484052
Zaheer, S., Kumar, D., Khan, M. T., Giyanwani, P. R., & Kiran, F. (2018). Epilepsy and cannabis: A literature review. Cureus, 10(9), 32–78. https://doi.org/10.7759/cureus.3278 PMid:30443449; PMCid:PMC6235654
Zou, S., & Kumar, U. (2018). Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. International Journal of Molecular Sciences, 19(3), 8–33. https://doi.org/10.3390/ijms19030833 PMid:29533978; PMCid:PMC5877694
Zuardi, A. W. (2008). Cannabidiol: From an inactive cannabinoid to a drug with wide spectrum of action. Brazilian Journal of Psychiatry, 30(3), 271–280. https://doi.org/10.1590/S1516-44462008000300015 PMid:18833429
Zylla, D., Steele, G., Eklund, J., Mettner, J., & Arneson, T. (2018). Oncology clinicians and the Minnesota medical cannabis program: A survey on medical cannabis practice patterns, barriers to enrollment and educational needs. Cannabis and Cannabinoid Research, 3(1), 195–202. https://doi.org/10.1089/can.2018.0029 PMid:30426072; PMCid:PMC6225592
Čulić, A., Bregar, B., & Macur, M. (2021). Raba konoplje v medicinske namene: integrativni pregled literature. Obzornik zdravstvene nege, 55(4), 274–286. https://doi.org/10.14528/snr.2021.55.4.3063
Prenosi
Objavljeno
Kako citirati
Številka
Rubrike
Licenca
Avtorske pravice (c) 2021 Obzornik zdravstvene nege
To delo je licencirano pod Creative Commons Priznanje avtorstva 4.0 mednarodno licenco.
Na Obzornik zdravstvene nege, Ob železnici 30A, 1000 Ljubljana, prenašam naslednje materialne avtorske pravice: pravico reproduciranja v neomejeni količini, in sicer v vseh poznanih oblikah reproduciranja, kar obsega tudi pravico shranitve in reproduciranja v kakršnikoli elektronski obliki (23. čl. Zakona o avtorski in sorodnih pravicah – v nadaljevanju ZASP); pravico distribuiranja (24. čl. ZASP); pravico dajanja na voljo javnosti vključno z dajanjem na voljo javnosti prek svetovnega spleta oz. računalniške mreže (32.a čl. ZASP); pravico predelave, zlasti za namen prevoda (33. čl. ZASP). Prenos pravic velja za članek v celoti (vključno s slikami, razpredelnicami in morebitnimi prilogami). Prenos je izključen ter prostorsko in časovno neomejen.
